Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs. Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.Ĭoadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.Ĭaution and close monitoring for development of hypotension is advised during coadministration of these agents. Optibet is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane stabilizing activity. In addition, beta(1)-selective blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. They are routinely prescribed in patients with ischemic heart disease.

Drugs such as betaxolol that block these receptors therefore have the reverse effect: they lower the heart rate and blood pressure and hence are used in conditions when the heart itself is deprived of oxygen.

Activation of beta(1)-receptors (located mainly in the heart) by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Optibet is used to treat hypertension, arrhythmias, coronary heart disease, glaucoma, and is also used to reduce non-fatal cardiac events in patients with heart failure. Optibet is a competitive, beta(1)-selective (cardioselective) adrenergic antagonist.

It also causes the reduction of intraocular pressure by decreasing the production of aqueous humour. It lacks intrinsic sympathomimetic but has little membrane-stabilising activity. Optibet is a cardioselective β-blocker which has greater affinity for β1-receptors and has little or no effect on β2-receptors.

Optibet kivis